Ivan Chun Hang Lam

Ivan Chun Hang Lam

Auto-generated profile, based on publicly available information

Ivan Chun Hang Lam

Pharmaco- and Device Epidemiology, Health Data Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ILIvan Chun Hang Lam
Ivan Chun Hang Lam
RZRan Zhang
Ran Zhang
KMKenneth Keng Cheung Man
Kenneth Keng Cheung Man
CWCarlos K H Wong
Carlos K H Wong
CCCeline Sze Ling Chui
Celine Sze Ling Chui
EWEric Yuk Fai Wan
Eric Yuk Fai Wan
The persisting risk of long-term health consequences of SARS-CoV-2 infection and the protection against such risk conferred by COVID-19 vaccination remains unclear. Here we conducted a retrospective territory-wide cohort study on 1,175,277 patients with SARS-CoV-2 infection stratified by their vaccination status and non-infected controls to evaluate the risk of clinical sequelae, cardiovascular and all-cause mortality using a territory-wide public healthcare database with population-based vaccination records in Hong Kong. A progressive reduction in risk of all-cause mortality was observed over one year between patients with SARS-CoV-2 infection and controls. Patients with complete vaccination or have received booster dose incurred a lower risk of health consequences including major cardiovascular diseases, and all-cause mortality than unvaccinated or patients with incomplete vaccination 30-90 days after infection. Completely vaccinated and patients with booster dose of vaccines did not incur significant higher risk of health consequences from 271 and 91 days of infection onwards, respectively, whilst un-vaccinated and incompletely vaccinated patients continued to incur a greater risk of clinical sequelae for up to a year following SARS-CoV-2 infection. This study provided real-world evidence supporting the effectiveness of COVID-19 vaccines in reducing the risk of long-term health consequences of SARS-CoV-2 infection and its persistence following infection.

1 June 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
QLQiuying Liao
Qiuying Liao
ILIvan C.H. Lam
Ivan C.H. Lam
HLHinson H.S. Lin
Hinson H.S. Lin
LWLeon T.L. Wan
Leon T.L. Wan
JLJason C.K. Lo
Jason C.K. Lo
JLJenny K. W. Lam
Jenny K. W. Lam

26 September 2023 in Communications Medicine
Verified
Journal Article
Open access
PDF file
YCYi Chai
Yi Chai
RCRachel Yui Ki Chu
Rachel Yui Ki Chu
YHYuqi Hu
Yuqi Hu
ILIvan Chun Hang Lam
Ivan Chun Hang Lam
FCFranco Wing Tak Cheng
Franco Wing Tak Cheng
FLFrancisco Lai
Francisco Lai
Background: Preclinical evidence suggests that certain antipsychotic medications may inhibit the development of lung cancer. This study aims to investigate the association between incident lung cancer and different cumulative exposure periods of flupentixol or any antipsychotics. Methods: Using electronic health records from the Hospital Authority in Hong Kong, this nested case-control study included case participants aged 18 years or older with newly diagnosed lung cancer after initiating antipsychotics between January 1, 2003, and August 31, 2022. Each case was matched to up to ten controls of the same sex and age, who were also antipsychotic users. Multivariable conditional logistic regression models were conducted to quantify the association between lung cancer and different cumulative exposure times of flupentixol (0–365 days [ref]; 366–1825 days; 1826+ days) and any antipsychotics (1–365 days [ref]; 366–1825 days; 1826+ days), separately. Results: Here we show that among 6435 cases and 64,348 matched controls, 64.06% are males, and 52.98% are aged 65–84 years. Compared to patients with less than 365 days of exposure, those with 366–1825 days of exposure to flupentixol (OR = 0.65 [95% CI, 0.47–0.91]) and any antipsychotics (0.42 [0.38–0.45]) have a lower risk of lung cancer. A decreased risk is observed in patients who have 1826+ days of cumulative use of any antipsychotics (0.54 [0.47–0.60]). Conclusions: A reduced risk of lung cancer is observed in patients with more than one year of exposure to flupentixol or any antipsychotics. Further research on the association between lung cancer and other antipsychotic agents is warranted.

8 July 2025 in Journal of the Royal Society of Medicine
Verified
Journal Article
Closed access
ILIvan Chun Hang Lam
Ivan Chun Hang Lam
YCYi Chai
Yi Chai
KMKenneth Keng Cheung Man
Kenneth Keng Cheung Man
WLWallis Cheuk Yin Lau
Wallis Cheuk Yin Lau
HLHao Luo
Hao Luo
IWIan Chi Kei Wong
Ian Chi Kei Wong
Objectives: To generate comprehensive evidence on the risk of clinical sequelae involving different organ systems over time after coronavirus disease 2019 (COVID-19) infection. Design: Multinational retrospective cohort study. Setting: Electronic medical records from the US, UK, France, Germany and Italy standardised to the Observational Medical Outcomes Partnership Common Data Model. Participants: A total of 303,251 individuals with a COVID-19 infection between 1 December 2019 and 1 December 2020 and propensity score matched non-COVID-19 comparators from 22,108,925 eligible candidates. Main outcome measures: Incidence of 73 clinical sequelae involving multiple organ systems including the respiratory, cardiovascular, dermatological and endocrine systems over the short- (0–6 months), medium- (6–12 months) and long-term (1–2 years) after COVID-19 infection. The hazard ratio (HR) and 95% confidence interval (95% CI) of individual disease outcomes were estimated using Cox proportional hazard regression. Results: Individuals with COVID-19 incurred a greater risk of clinical sequelae involving multiple organ systems including respiratory (France HR 2.23, 95%CI [2.10,2.37] to Italy 13.13 [11.80,14.63]), cardiovascular (Germany 1.39 [1.30,1.50] to US 1.79 [1.74,1.85]) and dermatological (UK 1.13 [1.01,1.25] to Italy 1.77 [1.42,2.21]) disorder over the short-term. While the risk of clinical sequelae has largely subsided during the medium-term, the risk of cardiovascular- (US 1.16 [1.11,1.21], France 1.10 [1.01,1.19]) and endocrine- (US 1.18 [1.12,1.24], Germany 1.15 [1.03,1.29]) related complications may continue to persist for up to two years. Conclusions: Through a network of multinational healthcare databases, this study generated comprehensive and robust evidence supporting the extensive multi-organ involvement of post-COVID-19 condition over the short-term period and the reduction in risk for most complications over the medium- and long-term.

1 June 2026 in Age and Ageing
Verified
Journal Article
Open access
RZRan Zhang
Ran Zhang
ILIvan Chun Hang Lam
Ivan Chun Hang Lam
XLXinyi Liu
Xinyi Liu
FSFeng Sun
Feng Sun
SZSiyan Zhan
Siyan Zhan
EWEric Yuk Fai Wan
Eric Yuk Fai Wan
Background: With the rise in older population globally, the optimal blood pressure (BP) target for antihypertensive therapy in those aged 60 and above remains to be evaluated in the real-world practice. This study evaluated the effectiveness and safety of standard versus lower BP targets in old (aged 60–79) and very old (aged ≥80) patients with hypertension in real-world clinical settings. Methods: We emulated a target trial using electronic medical records from the Hong Kong Hospital Authority, including patients aged 60 years or above with a diagnosis of hypertension, uncontrolled BP and records of antihypertensives adjustments from 2008 to 2013. Patients were first categorized into 3 age groups (60–69, 70–79, ≥ 80) and then assigned to BP targets of either 130–140/80–90 mmHg or below 130/80 mmHg. Outcomes included major cardiovascular disease (CVD), end-stage renal disease, all-cause mortality and major adverse events related to antihypertensive treatment. Results: Of 132 430 eligible patients identified, 52 553, 28 661 and 7106 patients aged 60–69, 70–79 and ≥ 80 years had BP targets of 130–140/80–90 mmHg, respectively; 11 148, 5636 and 1203 of patients in the same age groups had targets below 130/80 mmHg. Lower BP target was associated with reduced overall CVD and all-cause mortality: aged 60–69 years (CVD HR: 0.91 [95% CI, 0.85–0.96]; all-cause mortality: 0.89 [0.81–0.98]), aged 70–79 years (CVD: 0.87 [0.82–0.93]; all-cause mortality: 0.84 [0.78–0.91]), and aged≥80 years (CVD: 0.77 [0.69–0.86]; all-cause mortality: 0.80 [0.72–0.89]). No significant increase in major adverse events was observed in any age group. Results were consistent across all subgroups. Conclusion: Lowering BP of below 130/80 mmHg in old and very old patients was associated with better cardiovascular and mortality outcomes without increased adverse events. These findings suggest that a lower BP target may be beneficial and safe for older patients with hypertension.

19 June 2019 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
JCJoanne Crook
Joanne Crook
ILIvan Lam
Ivan Lam
Aim To reduce the average length of stay (LoS) of paediatric inpatients requiring discharge medication (TTO’s) on the short stay pathway (Comet). Methods A paediatric multi-disciplinary team (MDT) used the model for improvement to identify stakeholders and key drivers for change. The Comet patient journey was mapped from A&E to discharge. Plan-Do-Study-Act (PDSA) cycles were used to reduce LoS, targeting the addition of a paediatric pharmacist to the morning ward round and use of over- label packs to facilitate nurse-led discharge for simple TTO’s required within 2 hours. Data was collected over a two week period in summer; PDSA 1 baseline data, one week prior to change; PDSA 2, one week after implementation. Baseline measurements included time taken to write, screen and dispense TTO and the average LoS. Data was collected via the electronic prescribing system (Lastword). Patients eligible for the Comet pathway were included for analysis. Results were analysed using Microsoft Excel. Ethics approval was not required for this study. Results PDSA one; 15 patients admitted onto the Comet pathway. 67% patients were admitted outside working hours. Six patients needed TTOs, 33% were written out of hours and all dispensed by pharmacy. Average time to writing TTO 14.6 hours (16minutes-44hhours); time to pharmacist clinical screen 19.4 hours (6 minutes – 21 hours); average time for pharmacy to dispense TTO after screening 2 hours (69–203 minutes); average LoS for all Comet patients 17.6 hours (8–44) and 26 hours (14–44) for those needing TTO’s. Post implementation 12 patients were eligible for the Comet pathway. 83% patients were admitted outside of hours. Six patients needed TTO’s, 16% were written out of hours and 33% were dispensed by the nursing team. Average time to writing TTO increased to 20.2 hours (14–26), average time to pharmacist clinical screen was reduced to 10 minutes (1–98) and average time for pharmacy to dispense TTO reduced to 57 minutes (47–74). Average LoS for Comet patients was similar to PDSA 1 at 17.7 hours (3–27) but reduced to 20.8 h0urs (5–27) for those needing TTO’s. Conclusion Increasing patient-facing time of pharmacists to improve outcomes is recommended by the Carter report. (1)Pressures in emergency-care to free up beds for patients means we need to look for creative solutions. (2) This study found the addition of a paediatric pharmacist to the ward round increased efficiency of writing, screening and dispensing TTO’s - dramatically reducing time to screening TTO’s; and the average LoS by 5 hours. The pharmacist was aware of Comet discharges at the time of decision to discharge and was on hand to resolve medication related issues. New doctors in August could explain the increased time to writing TTO’s in the second week. Promotion of nurse-led discharge via over-label packs reduced the number of TTO’s sent to pharmacy. Limitations include2 weeks of data over summer were analysed and non-paediatric hospital activity would impact pharmacy dispensing time. Future work will test how pharmacist transcribing TTO’s on the ward round affect Los and to review pharmacist clinical interventions to assess impact on outcomes. References Department of Health. Carter report: Unwarranted variation: A review of operational productivity and performance in English NHS acute hospitals. 5thFebruary 2016. Royal College of Paediatrics and Child Health. Standards for Short-Stay Paediatric Assessment Units (SSPAU). March 2017.